anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a hemoglobin-containing liposome, containing an aqueous solution of hemoglobin in a high concentration in a liposome membrane consisting essentially of a hydrogenated phospholipid, having high safety and useful as artificial erythrocytes stable to oxidation. CONSTITUTION:The aimed substance obtained by dissolving a liposome membranous material with &gt;=50%, preferably &gt;=80% hydrogenation ratio consisting essentially a hydrogenated phospholipid (e.g. lechithin or phosphatidylcholine) in an organic solvent, adding an aqueous solution of hemoglobin in 30-60wt./wt.% concentration, pressurizing the resultant solution with an inert gas and subjecting the pressurized solution to discharging treatment under a high pressure. A substance capable of imparting negative charge (e.g. phosphatidic acid) is added to prevent the liposome from aggregating. Conversion of the hemoglobin into methohemoglobin is suppressed by using the hydrogenated phospholipid. Thereby the amount of the phospholipid used can be reduced as compared with that of the hemoglobin.
NEW MATERIAL:A lactic compound expressed by formula I [R&lt;1&gt; is lower alkoxycarbonyl-(lower)-alkyl or nitro-substituted phenyl (lower)- alkoxycarbonyl-(lower)-alkyl; X is halogen], reactive derivative in carboxyl group of the lactic compound usable in acylation reaction and salts thereof. EXAMPLE:4-Chloro-2-methoxycarbonylmethoxyimino-3-oxolactic acid. USE:Useful as a syn isomer of 7-acylamino-3-vinylcepharosporanic acid derivative having antimicrobial activity and synthetic intermediate for salts permissible as medicine thereof. PREPARATION:The aimed compound expressed by formula I is obtained from a compound expressed by formula II. Specifically, the aimed compound is obtained from 2-methoxycarbonylmethoxytmino-3-oxolactic acid tert. butylester obtained by starting from 2-hydroxyimino-3-oxolactic acid tert. butylester and sulfuryl chloride.
A system for creating custom fragrances is described that allows a customer to interact with an employee and a Perfumer&#39;s Organ to interactively select several scents for base, middle and top notes. They can then iteratively adjust the scents chosen. In one embodiment, the scents selected by a customer are provided to a computing device having a prestored table which separates the scents into variable potency scents having variable perceived strengths and normal potency scents having standard, equal perceived strengths. The table indicates the amount of each variable potency scent to use to normalize the strengths. The remaining normal potency scents are then added with an equal amount. In an alternative embodiment, predetermined mixtures are provided to the computing device and used as ‘training data’ to adjust the coefficients of a generalized formula to create a prediction equation fit to the training data. The computing device receives the selected scents, the type of product to be made and the container size and uses the prediction equation to identify the amounts of each of the selected scents. In another optional embodiment, a filling device can automatically meter the scent liquids, a filling material, and provide them into the selected container. The filling device is driven by the computing device and determines the amounts of the selected scents and creates the custom fragrance according to one of the methods above.
PURPOSE:To prepare the titled preparation minimizing the oxidative decomposition reaction of the drug and the substrate material, by compounding a substrate containing a drug for transcutaneous absorption with powdery polymer having phenolic hydroxyl group. CONSTITUTION:A substrate containing a drug for transcutaneous absorption (e.g. corticosteroid, analgesic and anti-inflammatory agent, hypnotic sedative, tranquillizer, hypotensive drug, anesthetic, etc.) is compounded with 2X10&lt;-4&gt;-2wt%, preferably 5X10&lt;-4&gt;-5X10&lt;-1&gt;wt% powdery polymer having phenolic hydroxyl group [e.g. the compound of formula (X is OH, methyl, methoxy, etc.; R is H or t-butyl) and having a molecular weight of about 1,000-9,000]. The obtained drug for external use is preferably used in the form of ointment, suppository, poultice, liniment, lotion or tape. A tape is one of extremely desirable drug forms from the viewpoint of the improvement in the effective utility of the drug and the simplicity of application.
The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck &amp; Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for sufficiently enhancing the melamine production-inhibiting effect of an ascorbic acid compound.  &lt;P&gt;SOLUTION: The subject skin care preparation for external use is characterized by containing (1) ascorbic acid and/or its derivative and (2) centaureidine having a chemical structure of the formula and/or its salt in an amount of 0.001 to 1 mass %. The ascorbic acid and/or its derivative are preferably an ascorbic acid phosphate, ascorbic acid-2-glucoside or its salt. The centaureidine is preferably prepared by subjecting an alcohol extract of a plant in the family Compositae to a solution extraction using ethyl acetate and water, concentrating the ethyl acetate phase, and then subjecting the concentrated phase to a fractional purification with column chromatography using silica gel as a carrier. The plant in the Compositae includes Achilea millefolium, Centaurea cyanus, Tanacetum parthenium, Acroptilon repens, Smallanthus sonchifolius, Lepidium meyenii, and Eupatorium rebaudianum.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To secure the safety and effectiveness of general medicines provided to patients by providing a computer system for storing and processing information for unitarily managing medicinal items and components and chemicals, etc., for acting on a human body. SOLUTION: After a start screen is displayed on a display device 3, a &#39;continue&#39; button is pressed and the menu screen of a first stage is displayed. One of displayed six frames for indicating the classifications of the general medicines is selected. Then, the menu screen of a second stage is displayed and the required one is selected from among five groups. Then, after displaying the menu screen of a third stage and selecting a required medicine group, the component menu of a forth stage and the formulation menu screen of a fifth stage are displayed. Then, desired selection is performed in a sixth stage. Then, selection elements pertinent to the selection operations of first - fifth stages are decided, the general medicine for satisfying them is selected from the information of the medicinal items or the like and relating information is displayed on the display device 3.
Cosmetic composition comprising a biodegradable polyester and an oily phase. The present invention relates to a cosmetic composition comprising a biodegradable polyester and an oil phase. A cosmetic composition comprising: from 70% to 99.9% by weight of a cosmetically acceptable base formulation comprising an oil phase; 0.1 to 30% by weight of at least one Polyhydroxyalkanoate (PHA) in the form of particles having an average diameter (d 50) of 0.1 to 100 μm; the percentages are expressed relative to the total weight of the composition. PHA in granular form acts as a texturizing agent and ensures the desired consistency and fluidity of the cosmetic composition during application, as well as a reduction in greasiness. In fact, PHA granules have a strong capacity to absorb oily substances, so that they minimize the greasy effect and absorb excess sebum, making the skin less reflective. In addition, they contribute to the so-called &#34;soft focus&#34; effect, i.e. an immediate filling and smoothing effect on wrinkles and skin&#39;s furrows, giving the skin greater radiance and firmness.
PURPOSE: A pharmaceutical composition containing an Allium tuberosum Rottler extract possessing xanthine oxidase inhibitory activity as an effective ingredient is provided. The extract is used as a pharmaceutical composition and a health food for prevention and treatment of gout or comorbid disorders of gout. The comorbid disorders of gout include hypertension, obesity, hyperlipidemia, arteriosclerosis, diabetes, chronic alcohol intoxication, cancer, coronary heart disease, cataract, Down&#39;s syndrome, hepatitis, ischemia or reperfusion damage, rheumatoid arthritis or cardiac insufficiency. CONSTITUTION: The pharmaceutical composition contains: the crude extract of Allium tuberosum Rottler which is extracted in lower alcohol such as water, ethanol and methanol, or a mixed solvent thereof, and its solvent extract which is soluble in a nonpolar solvent or a polar solvent; and additionally carriers, excipients and diluents. The recommend dosage of the extract ranges from 0.1 to 100mg/kg/day. A health beverage contains 0.02 to 10g of the extract on the basis of 100ml of beverage. The nonpolar solvent is selected from hexane, chloroform, dichloromethane or ethyl acetate, the polar solvent is selected from acetone, butanol, ethanol, methanol or water.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a polyphenol extract from Litchi chinensis Sonn. pericarp and obtained the extract and its use.  &lt;P&gt;SOLUTION: The method for producing an extract abundantly containing a polyphenol contained in the Litchi chinensis Sonn. pericarp comprises extracting a Litchi chinensis Sonn. pericarp at two stages, removing the water-insoluble fraction of the first-stage extract, re-extracting the polyphenol component of the water-insoluble fraction with a solvent, combining the obtained extracts, feeding the combined extracts to a reversed-phase column and eluting the extracts with a low-concentration hydrous alcohol to give an extract. The obtained extract contains a high-concentration polyphenol, has an excellent antioxidant action and is mixed with a food and beverage, a cosmetic or a medicine.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
It has been found that agents which inhibit the interaction between the band 3 protein and its ligand (hereafter sometimes referred to as &#34;interaction inhibitors&#34; or &#34;inhibitors&#34;), CD36/thrombospondin, can also be used to enhance thrombolysis. The inhibitors can be peptides which contain sequences present in exofacial loops of the band 3 protein, or can be non-natural, D-isomer forms of the same sequences, or can be peptides, peptidomimetics, or non-peptidic molecules which interfere with band 3 protein-ligand interactions. One preferred group of such inhibitors comprises peptides characterized by the sequence motifZ2Z3Z2UX-UUUX- (SEQ ID NO:44),wherein Z2 represents a hydrophobic residue, U represents unobstructive residues, Z3 is either Z2 or an unobstructive residue and X- represents negatively charged residues. Another preferred group of such inhibitors comprises peptides characterized by the sequence motifZ1UKUUUX+ (SEQ ID NO:45),wherein Z1 is selected from the group consisting of tyrosine, phenylalanine and alanine; K is a lysine residue; U represents unobstructive residues; and X+ is a positively charged residue. The reverse sequences of these peptides are also active. The inhibitors of the subject method can be administered alone or in combination with one or more additional therapeutic agents. Administration can be oral, intravenous or by other means, in amounts between about 0.1 mg/kg to about 20 mg/kg.
A resin-drug compound comprises a derivative of 2-aminopropan-1-one of formula &lt;FORM:0928304/IV(a)/1&gt; wherein R1 and R2 are C1 to C4 alkyl and R3 is phenyl or substituted phenyl, said derivative being adsorbed in ion-exchange relationship on a cation exchange resin. The preferred derivative is 1-phenyl-2-diethylaminopropan-1-one (otherwise called diethylpropion), and the resin may be sulphonated, cross-linked polystyrene or cross-linked polymethacrylic acid.  The products find application in pharmaceutical preparations for appetite depressant purposes.ALSO:A pharmaceutical or veterinary composition having appetite depressant activity, comprises a resin-drug compound of a 2-aminopropan-1-one of formula &lt;FORM:0928304/VI/1&gt; wherein R1 and R2 are C1 to C4 alkyl and R3 is phenyl or substituted phenyl, adsorbed in ion-exchange relationship on a cation exchange resin. The preferred resin-drug compounds are derived from 1-phenyl-2-diethyl-aminopropan-1-one and sulphonated, cross-linked polystyrene or cross-linked polymethacrylic acid.  The compositions may be in forms for oral administration, e.g. tablets, pills, capsules, powders, granules, syrups, emulsions and dispersions, such forms comprising conventional pharmaceutical excipients and optionally other therapeutic agents as may improve the reduction of the undesirable side effects of the 2-aminopropan-1-one compound.  An example also describes a suppository.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an embedding type medical device which has broad thrombolysis characteristics.  &lt;P&gt;SOLUTION: The medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
6-Demethyltetracycline antibiotics, e.g. 6-demethyl chlortetracycline are produced by culturing a tetracycline-antibiotic-producing strain of a species of the genus Streptomyces in a nutrient medium containing assimilable carbon and nitrogen sources, a methylation inhibitor being added to the fermentation medium gradually so that the ratio of the amount of nucleic acids and proteins formed related to that of the inhibitor added is maintained substantially constant during the course of the fermentation.  The methylation inhibitor may be a compound of general formula &lt;FORM:1091046/C2/1&gt; where R is a substituted or unsubstituted guanidine, thiazole, pyrimidine or pyrazine radical, e.g. p-aminobenzene sulphonyl guanidine, 2 - (p - aminobenzene sulphonyl) - 4,6-dimethyl pyrimidine, 2-(p-aminobenzene sulphonyl) - 6 - methoxy - pyridazine and 2 - (p-aminobenzene sulphonyl) - 4 - methyl - thiazole. For the production of 6-dimethyl chlorotetracycline or 6-demethylbromotetracycline, the fermentation medium contains chloride or bromide ions respectively in an amount greater than 50g /ml.  If 6-demethyltetracycline is desired, the fermentation medium should contain less than 50 g /ml. of chloride or bromide ions and/or contain chlorination or bromination inhibitors. Preferably, the whole of the methylation inhibitor is added during the first 24 hours of fermentation.
Use of a compound (I) interacting with brain-derived nerve growth factor (BDNF)-signal transduction cascade for the production of a medicament to treat phantom phenomena of acute tinnitus and/or phantom pain in human or animal. Independent claims are also included for: (1) diagnosing phantom phenomena of the acute tinnitus and/or phantom pain in human or animal, comprising supplying a biological sample, determining the level of the expression of BDNF in the biological sample, comparing the level with a reference value from a healthy organism, and correlating a level lying over the healthy organism with a positive diagnosis; and (2) treating phantom phenomena of the acute tinnitus and/or phantom pain in human or animal, comprising supplying a medicament that exhibits a substance interacting with BDNF signal transduction cascade, and applying the medicament locally to the organism, and optionally repeating the method. ACTIVITY : Auditory; Analgesic. MECHANISM OF ACTION : Brain-derived nerve growth factor (BDNF)-signal transduction cascade blocker; BDNF-signal transduction cascade inhibitor; Gamma aminobutyric acid receptor agonist; L-type-Ca ++&gt;-channel antagonist; Cyclic adenosine monophosphate response element binding protein (CREP) antagonist; Glutamate antagonist; Mitogen activated protein-kinase-inhibitor; Calmodulin-dependent kinase-inhibitor; Tyrosine kinase linked receptor (trkB) antagonist. The ability of (I) to inhibit BDNF-signal transduction cascade was tested in cochlea. (I) Significantly removed the expressions of BNDF Exon-IV.
FIELD: medicine, pharmaceutical technology. SUBSTANCE: invention relates to medicinal preparations containing radioactive substances. Method involves irradiation of yttrium oxide by fast neutrons, dissolving the obtained mixture of isotopes in acid and chemical isolation of the end product from solution with acidity from 1.5 to 4.5 M by sorption on strontium-specific sorbent. In special cases the following crown-ethers applied on a solid carrier are used as strontium-specific sorbents: 18-crown-6, dicyclohexano-18-crown-6, dicyclo-hexano-18-crown-6 with hydrophobic substitutes. It is possible to use the following crown-ethers applied on a solid carrier as strontium-specific sorbents: dicyclohexano-18- crown-6 containing alkyl substitutes, in part, crown-ether 4,4&#39;(5&#39;)-di-(tert.-butylcyclohexano)-18-crown-6. Polymer of polyacrylate structure or copolymer of styrene with divinylbenzene is used as a solid carrier. Invention can be used for therapy of oncological diseases and for production of β-sources using in instrument making and biological investigations. EFFECT: increased yield of product, decreased consumption of reagents. 8 cl, 1 dwg
The present invention pertains to the field of medicine and may be used for producing a specific antiserum as well as for carrying out immunological diagnoses of malignant tumours. This method for producing an antiserum involves sampling an embryo at the foetal stage from animals of a same genetic type so as to obtain a cell suspension. After immunisation, this method involves sampling spleen cells from the animal, separating lymphocytes and immunising the animal of the same genetic line using the lymphocyte suspension. An antiserum is then obtained and cells originating from healthy organs of the same animals are added to said antiserum. The mixture is finally decanted and the liquid located above the sediments is filtered. In order to carry out a diagnosis, the filtrate is added to the subject&#39;s blood and the results are obtained by immuno-fluorescence, by blood tests or using other methods of immunological diagnosis. It is thus possible to diagnose a tumour when the reliable values obtained differ from reference values.
Described are methods, kits, apparatus, and compositions for integumentary system therapy. For example, a method for therapy may include providing a subject in need of therapy for a condition. The condition may be associated with a substrate located in the subject&#39;s integumentary system. The method may include contacting a therapeutic agent and the substrate in the subject&#39;s integumentary system. The method may include modulating a depth of at least one ionic species in the subject&#39;s integumentary system. The at least one ionic species may include one or more of: the therapeutic agent; a bound therapeutic agent:substrate complex; and a reaction product of one or both of the therapeutic agent and the substrate. The method may be effective to at least partly ameliorate the condition in the subject.
Chronic kidney disease (CKD) in the late stage is defined as the progressive and irreversible loss of renal functions due to various reasons leading to a decrease in glomerular filtration rate (GFR). It is estimated that there are 37 million diagnosed cases of CKD worldwide, with CKD ranking ninth among the leading causes of death in the United States. Among the treatment options for end-stage renal failure are hemodialysis (HD), peritoneal dialysis (PD), and transplantation (TX), with HD being the most preferred method by patients. According to the 2022 registration data from the Turkish Society of Nephrology, there were a total of 86,665 CKD patients by the end of 2022, with 71.22% of these patients (n: 61,723) receiving HD treatment.

In patients undergoing HD treatment, the weight gained between two dialysis sessions is defined as interdialytic weight gain (IDWG). The development of hypervolemia due to excessive weight gain can lead to both systemic illnesses and problems during the treatment process. Particularly, cardiovascular problems rank first among systemic illnesses (43%), leading to complications related to excessive ultrafiltration (UF) during the treatment process (hypotension, muscle cramps, nausea-vomiting). Elevated IDWG generally leads to hypertension, left ventricular hypertrophy, pulmonary edema, congestive heart failure, and higher mortality rates due to all these cardiac problems. The ideal IDWG is expected to be in the range of 1-2 kg or 3-5%. In a study, it was reported that 85% of HD patients had an IDWG of \&gt;1.5 kg, especially young, male, and diabetic patients tend to have high IDWG, which leads to an increase in mortality rates due to cardiovascular diseases. Similar results have been reported in many other studies. According to estimates from the United States Renal Data System, cardiovascular events account for 40% of deaths. The 2022 data from the Turkish Society of Nephrology reports that cardiovascular diseases were the leading cause of death (46.3%) among HD patients in our country by the end of 2022. Similar results have been reported in many other studies.

The concept of individual management is defined as the ability of patients with a chronic disease to manage their illness, change their lifestyle, and therefore, live with a chronic disease. Individual management in HD patients requires various skills, including adherence to recommended treatment (e.g., weight gain, nutrition), effective symptom management, problem-solving ability, disease control, decision-making, and communication with the healthcare team. Therefore, increasing individual management in HD patients is known to be associated with increased treatment adherence and better clinical outcomes. In a study, it was found that a mobile application-based individual management program developed to determine the effects of HD patient role behaviors, basic psychological needs, and individual management was effective in increasing patients individual management.